Dr. Jens Francis Graversen, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1002 Jefferson St., Suite 450, Laurel, MS 39440 Phone: 601-428-0438 Fax: 601-425-5553 |
News Archive
In the midst of Zimbabwe's growing humanitarian crisis, U.N. agencies on Monday released a revised statement of appeal for foreign donations totaling $718 million for "food, clean water, AIDS medicines and other aid – up from an estimate of $550 million in November," the AP/Washington Post reports (Shaw, AP/Washington Post, 6/1).
BioMarin Pharmaceutical Inc. announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe disease. An investigational new drug application (IND) for BMN-701 has been submitted, investigational material has been manufactured and a Phase I/II study is expected to start in the first quarter of 2011.
The following news release is being issued by CIPA - Canadian mail-order drug importation may become illegal soon due to new regulations proposed by the Liberal Government. After quietly supporting the practice for four years, the Liberals made a conspicuous about face after President Bush's November visit to Canada.
Hamilton Thorne Ltd., a leading provider of advanced laser systems and instruments for the stem cell research and fertility clinic markets, today announced the launch of the Staccato(TM) multi-pulse laser system at the 8th Annual Meeting of the International Society of Stem Cell Research (ISSCR), June 16-19, 2010, in San Francisco, CA. Staccato(TM) will add to the functionality of the XYClone(R) laser system, providing the ability of near-continuous application of the laser to the sample through rapid pulsing of the beam.
EKR Therapeutics, Inc., a specialty pharmaceutical company focused on commercializing acute-care hospital products, today announced that the US Patent and Trademark Office has issued two new patents covering methods of treatment and methods of preparation for the Company's Ready-to-Use (RTU) Cardene® I.V. (nicardipine hydrochloride) Premixed Injection.
› Verified 8 days ago